These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 29262900)

  • 21. The Importance of FISH Signal Cut-off Value and Copy Number Variation for 1q21 in Newly Diagnosed Multiple Myeloma: Is it Underestimated?
    Gao L; Liu Y; Li Y; Feng L; Wang Z; Wen L; Wang F; Huang X; Lu J; Lai Y
    Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):535-544. PubMed ID: 35292207
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: Adverse effect of 1q21 gains.
    Chang H; Trieu Y; Qi X; Jiang NN; Xu W; Reece D
    Leuk Res; 2011 Jan; 35(1):95-8. PubMed ID: 20537706
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chromosome 1q21 Aberrations Are Poor Prognostic Factors for Newly Diagnosed Multiple Myeloma Patients.
    Wang T; Geng C; Yang G; Zhou H; Zhang Z; Jian Y; Chen W
    J Clin Lab Anal; 2024 Sep; 38(17-18):e25072. PubMed ID: 39263925
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 1q21 amplification with additional genetic abnormalities but not isolated 1q21 gain is a negative prognostic factor in newly diagnosed patients with multiple myeloma treated with thalidomide-based regimens.
    Grzasko N; Hus M; Chocholska S; Pluta A; Hajek R; Dmoszynska A
    Leuk Lymphoma; 2012 Dec; 53(12):2500-3. PubMed ID: 22497640
    [No Abstract]   [Full Text] [Related]  

  • 25. Plasma cell labeling index correlates with deletion of 13q14 in multiple myeloma.
    Li C; Chen L; Gao X; Qu X; Shen W; Yang R; Zhang R; Qiu H; Xu J; Lu H; Li J
    Leuk Lymphoma; 2011 Feb; 52(2):260-4. PubMed ID: 21133734
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma.
    Merz M; Hielscher T; Seckinger A; Hose D; Mai EK; Raab MS; Goldschmidt H; Jauch A; Hillengass J
    Am J Hematol; 2016 Nov; 91(11):E473-E477. PubMed ID: 27508939
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Investigation of chromosome 1 aberrations in patients with multiple myeloma using cIg-FISH method and its significance].
    Yang RF; Li CM; Qiu HR; Lu H; Wu HX; Xu JR; Li JY; Chen LJ
    Zhonghua Xue Ye Xue Za Zhi; 2010 Dec; 31(12):804-8. PubMed ID: 21223735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p.
    Neben K; Lokhorst HM; Jauch A; Bertsch U; Hielscher T; van der Holt B; Salwender H; Blau IW; Weisel K; Pfreundschuh M; Scheid C; Dührsen U; Lindemann W; Schmidt-Wolf IG; Peter N; Teschendorf C; Martin H; Haenel M; Derigs HG; Raab MS; Ho AD; van de Velde H; Hose D; Sonneveld P; Goldschmidt H
    Blood; 2012 Jan; 119(4):940-8. PubMed ID: 22160383
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patients with newly diagnosed multiple myeloma and chromosome 1 amplification have poor outcomes despite the use of novel triplet regimens.
    Biran N; Malhotra J; Bagiella E; Cho HJ; Jagannath S; Chari A
    Am J Hematol; 2014 Jun; 89(6):616-20. PubMed ID: 24616227
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The significances of 13q14 deletion for development and prognosis of multiple myeloma].
    Li Q; An G; Li CW; Xu Y; Deng SH; Liu XP; Qi JY; Wang YF; Zou DH; Zhao YZ; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2011 Apr; 32(4):217-20. PubMed ID: 21569701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 1q21+ is associated with poor prognosis in newly diagnosed multiple myeloma patients with extramedullary disease: a retrospective study.
    Gao S; Dong F; Yang P; Chen Y; Wang Y; Wang J; Shi Y; Jing H
    Ann Hematol; 2024 Jun; 103(6):1979-1987. PubMed ID: 38206369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Presentation and outcomes of patients with multiple myeloma harboring gain or amplification of 1q21 and receiving novel agent therapies: results from a single-center study.
    Chen H; Zhou N; Shi H; Yu W; Wu L; Zhou F
    Hematology; 2023 Dec; 28(1):2177979. PubMed ID: 36794720
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma.
    Chang H; Qi X; Jiang A; Xu W; Young T; Reece D
    Bone Marrow Transplant; 2010 Jan; 45(1):117-21. PubMed ID: 19448682
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Analysis of the efficacy and prognosis on first-line autologous hematopoietic stem cell transplantation of patients with multiple myeloma].
    Zou DH; Sui WW; Yi SH; An G; Xu Y; Li ZJ; Li CW; Qi JY; Zhao YZ; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2013 Apr; 34(4):299-303. PubMed ID: 23668200
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 1q21 gain but not t(4;14) indicates inferior outcomes in multiple myeloma treated with bortezomib.
    Du C; Mao X; Xu Y; Yan Y; Yuan C; Du X; Liu J; Fan H; Wang Q; Sui W; Deng S; Fu M; Li Z; Li C; Zhao J; Yi S; Liu L; Hao M; Zou D; Zhao Y; Qiu L; An G
    Leuk Lymphoma; 2020 May; 61(5):1201-1210. PubMed ID: 31842644
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in China.
    Gao W; Jian Y; Du J; Li X; Zhou H; Zhang Z; Yang G; Wang G; Tian Y; Li Y; Wu Y; Fu W; Li J; Chen W
    Cancer Med; 2020 Nov; 9(21):7819-7829. PubMed ID: 32881351
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma.
    Kiyota M; Kobayashi T; Fuchida S; Yamamoto-Sugitani M; Ohshiro M; Shimura Y; Mizutani S; Nagoshi H; Sasaki N; Nakayama R; Chinen Y; Sakamoto N; Uchiyama H; Matsumoto Y; Horiike S; Shimazaki C; Kuroda J; Taniwaki M
    Int J Hematol; 2012 May; 95(5):516-26. PubMed ID: 22426624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A retrospective analysis of cytogenetic and clinical characteristics in patients with multiple myeloma.
    He J; Yang L; Meng X; Wei G; Wu W; Han X; Zheng G; Zheng W; Ye X; Shi J; Xie W; Zhang J; Huang H; Lin M; Cai Z
    Am J Med Sci; 2013 Feb; 345(2):88-93. PubMed ID: 22986611
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical Efficacy and Prognosis of Double-Hit Multiple Myeloma Patients with Deletion P53 Treated with Regimen Based on Bortezomib].
    Wang DM; Chen YY; Meng Z; Zhang YX; Guo SQ; Li YH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1221-1227. PubMed ID: 32798402
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion.
    Sagaster V; Ludwig H; Kaufmann H; Odelga V; Zojer N; Ackermann J; Küenburg E; Wieser R; Zielinski C; Drach J
    Leukemia; 2007 Jan; 21(1):164-8. PubMed ID: 17096015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.